Exploring potential molecular resistance and clonal evolution in advanced her2-positive gastric cancer under trastuzumab therapy

HIGHLIGHTS

• who: Qi Xu from the Study design and participants This study was conducted at the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) in accordance with a human research ethics committee-approved protocol (Approval NoIRB-2022-70). The study included , patients with histologically confirmed GC or gastroesophageal junction cancer (GEJC) who received trastuzumab in combination with chemotherapy as the first-line treatment between April , and March, . Informed consent was obtained from all participants. The study design is shown in Supplemental Fig. , and Supplemental Methods. have published the paper: Exploring potential molecular resistance . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.